Lidocaine for Pain Management
(NeuCLA Trial)

Recruiting in Palo Alto (17 mi)

Overseen byKeith M Vogt, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Keith M Vogt

No Placebo Group

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this study is to characterize the effects of intravenous lidocaine on pain processing and cognitive function. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will consist of 1 visit and involves no long-term follow up.

Research Team

Keith M Vogt, MD, PhD

Principal Investigator

University of Pittsburgh

Eligibility Criteria

This trial is for healthy adults aged 18 to 70 with normal body weight. Participants must have a valid email and phone number, not be pregnant, have no metal implants or severe tattoos, no history of seizures or heart rhythm problems, not claustrophobic, and not on certain medications like antiepileptics or antidepressants.

Inclusion Criteria

Have a valid email address and phone number throughout the study

You must have a regular body weight.

You should be in good overall health.

See 3 more

Exclusion Criteria

You regularly take pain medication for chronic pain at least three times a week.

You have a past of seizures.

You have a history of irregular heartbeats, like heart block or atrial fibrillation.

See 14 more

Treatment Details

Interventions

Lidocaine IV (Local Anesthetic)

Trial OverviewThe study tests how intravenous lidocaine affects pain processing and cognitive function using brain imaging (fMRI). It's a short-term study with one visit and focuses on the changes in brain activity related to pain relief provided by lidocaine.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: LidocaineExperimental Treatment2 Interventions

Subjects will receive lidocaine during the drug portion of the experiment.

Lidocaine IV is already approved in Canada for the following indications: